BLVIS A Blue Vision A

Settlement - Purchase of shares

Settlement - Purchase of shares

2 June 2023

Announcement no. 33

Inside information

Settlement - purchase of shares

In connection with completion of Pharma Equity Group A/S' (the "Company") purchase of Reponex Pharmaceuticals A/S ("Reponex"), the new shares issued to former larger shareholders in Reponex were subject to a lock-up undertaking (the "Lock-Up Undertaking").

As a shareholder by mistake, and without having obtained consent from the Company, has divested shares in the Company in violation of the Lock-Up Undertaking, such shareholder has, as a consequence, undertaken towards the Company and the Company's board of directors to buy back in the market minimum 6,795,163 shares (with a nominal value of DKK 1.0 each). The share purchase shall be completed no later than on 21 June 2023.

For further information, please contact:    

Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: 40 22 21 14 

Peter M. Eriksen, Chair of the Board of Directors of Pharma Equity Group A/S, phone: 51 99 66 00. 



EN
02/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE

Afsøgning af muligheder angående en rettet kapitalforhøjelse til marke...

Afsøgning af muligheder angående en rettet kapitalforhøjelse til markedskurs i Pharma Equity Group A/S 8. maj 2024 Meddelelse nr. 16 Afsøgning af muligheder angående en rettet kapitalforhøjelse til markedskurs i Pharma Equity Group A/S I forlængelse af selskabsmeddelelse nr. 15 fra 8. maj 2024 angående indkaldelse til en ekstraordinær generalforsamling den 3. juni 2024 med henblik på at nedsætte selskabets kapital, har bestyrelsen i Pharma Equity Group A/S ("PEG") i dag truffet beslutning om at afsøge mulighederne for at styrke PEG's arbejdskapital ved en kapitalforhøjelse til markedspr...

 PRESS RELEASE

Exploration of options regarding a directed capital increase at market...

Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S      8 May 2024Announcement No. 16  Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S In continuation of company announcement no. 15 of 8 May 2024 regarding notice of an extraordinary general meeting, to be held on 3 June 2024. with a view to reducing the company's capital, the Board of Directors of Pharma Equity Group A/S ("PEG") has today decided to explore the possibilities of strengthening PEG's working capital through a capital in...

 PRESS RELEASE

Indkaldelse til ekstraordinær generalforsamling i Pharma Equity Group ...

Indkaldelse til ekstraordinær generalforsamling i Pharma Equity Group A/S 8. maj 2024 Meddelelse nr. 15 Indkaldelse til ekstraordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til en ekstraordinær generalforsamling i Pharma Equity Group A/S ("PEG" eller "Selskabet") den: 3. juni 2024, kl. 15:30 på adressen Wihlborgs KantinerSlotsmarken 152970 Hørsholm Dagsordenen for den ekstraordinære generalforsamling er følgende: Forslag om at nedsætte Selskabets aktiekapitalBemyndigelse til dirigenten Punkt 1 – Forslag om at nedsætte Selskabets aktiekapital Bes...

 PRESS RELEASE

Notice convening the extraordinary general meeting of Pharma Equity Gr...

Notice convening the extraordinary general meeting of Pharma Equity Group A/S 8 May 2024 Announcement no. 15 Notice convening the extraordinary general meeting of Pharma Equity Group A/S The board of directors hereby convenes an extraordinary general meeting in Pharma Equity Group A/S ("PEG" or the "Company") to be held on:  3 June 2024, at 15:30 CEST at Wihlborg's CanteensSlotsmarken 15DK-2970 Hørsholm The agenda for the extraordinary general meeting is as follows: Proposal to reduce the Company's share capitalAuthorization to the chair of the general meeting Item 1 –  Proposal t...

 PRESS RELEASE

Storaktionærmeddelelse - Pharma Equity Group A/S

Storaktionærmeddelelse - Pharma Equity Group A/S      Storaktionærmeddelelse - Pharma Equity Group A/S  23. april 2024Selskabsmeddelelse nr. 14 Pharma Equity Group A/S har i henhold til kapitalmarkedslovens § 38 modtaget storaktionærmeddelelse om, at DMZ Holding ApS har erhvervet aktier i Pharma Equity Group A/S.  Som følge heraf har DMZ Holding ApS øget deres ejerandel til over 5% i Pharma Equity Group A/S.  For yderligere information, kontakt venligst:  Thomas Kaas Selsø, Adm. direktør i Pharma Equity Group A/S, telefon: Christian Vinding Thomsen, bestyrelsesformand i Pharma Equity Group...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch